ArticleBMC neurology2026
Identification of potential biological biomarkers for acute ischemic stroke based on integrated bioinformatics analyses.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Ischemic stroke is a major cause of disability and mortality worldwide, accounting for approximately 66% of all stroke cases. Stroke has been reported to cause approximately 6.5 million deaths annually, and the global disability-adjusted life years attributable to stroke are projected to exceed 200 million by 2030. Therefore, identifying reliable diagnostic biomarkers for acute ischemic stroke (AIS) and exploring their underlying molecular mechanisms are of great importance for early disease recognition and clinical intervention. Transglutaminases (TGases) are widely distributed in the central nervous system and play important roles in inflammatory responses, neural repair, and vascular regulation. In this study, multiple bioinformatics approaches were used to identify TGM2 as a candidate gene associated with AIS. Single-cell RNA sequencing (scRNA-seq) data were further integrated to analyze the expression pattern of TGM2 across different cell types and to explore its potential intercellular communication context. Finally, TGM2 expression was validated in peripheral blood samples from patients with AIS. This study provides new evidence supporting the potential involvement of TGM2 in AIS and its value as a candidate biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.